[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF [FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF [FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF
申请人:Tsantrizos Youla S.
公开号:US20130203702A1
公开(公告)日:2013-08-08
The present invention relates to novel compounds, compositions containing same and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds;
Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells
作者:Yih-Shyan Lin、Jaeok Park、Joris W. De Schutter、Xian Fang Huang、Albert M. Berghuis、Michael Sebag、Youla S. Tsantrizos
DOI:10.1021/jm201657x
日期:2012.4.12
Human farnesyl pyrophosphate synthase (hFPPS) controls intracellular levels of FPP and post-translational prenylation of small GTPase proteins, which are essential for cell signaling and cell proliferation. Clinical investigations provide evidence that N-BP inhibitors of hFPPS are disease modifying agents that improve survival of multiple myeloma (MM) patients via mechanisms unrelated to their skeletal effects. A new series of N-BPs was designed that interact with a larger portion of the GPP subpocket, as compared to the current therapeutic drugs, and rigidify the (KRRK367)-K-364 tail of hFPPS in the closed conformation in the absence of IPP. An analogue of this series was used to demonstrate inhibition of the intended biological target, resulting in apoptosis and down-regulation of ERK phosphorylation in human MM cell lines.
[EN] HETEROCYCLYL-PYRIDINYL-BASED BIPHOSPHONIC ACID, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, COMPOSITION THEREOF AND METHOD OF USE THEREOF<br/>[FR] ACIDE HÉTÉROCYCLYLE-PYRIDINYLE BISPHOSPHONIQUE, SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, COMPOSITION EN CONTENANT ET SON PROCÉDÉ D'UTILISATION
申请人:UNIV MCGILL
公开号:WO2011147038A1
公开(公告)日:2011-12-01
The present invention relates to novel compounds, compositions containing said compounds and methods for inhibiting human farnesyl pyrophosphate synthase or for the treatment or prevention of disease conditions using said compounds, which may also be useful in the inhibition of FPPS enzymes of microorganisms and protozoan parasites such as the groups of Leishmania, Plasmodium, Trypanosoma, Toxoplasma and Cryptosporidium.